Astrazeneca PLC (NYSE:AZN) has received a consensus rating of “Hold” from the twenty-four ratings firms that are covering the firm. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $39.50.

A number of research analysts have recently weighed in on AZN shares. JPMorgan Chase & Co. restated a “neutral” rating on shares of Astrazeneca PLC in a research report on Monday, August 8th. Shore Capital restated a “hold” rating on shares of Astrazeneca PLC in a research report on Wednesday, July 27th. Deutsche Bank AG restated a “buy” rating on shares of Astrazeneca PLC in a research report on Monday, October 10th. Citigroup Inc. restated a “buy” rating on shares of Astrazeneca PLC in a research report on Monday, November 7th. Finally, TheStreet upgraded Astrazeneca PLC from a “hold” rating to a “buy” rating in a research report on Friday, July 22nd.

Astrazeneca PLC (NYSE:AZN) opened at 27.40 on Monday. The company’s 50-day moving average price is $30.06 and its 200-day moving average price is $30.81. The stock has a market cap of $69.32 billion, a P/E ratio of 28.12 and a beta of 0.83. Astrazeneca PLC has a one year low of $26.97 and a one year high of $35.04.

Astrazeneca PLC (NYSE:AZN) last issued its quarterly earnings results on Thursday, November 10th. The company reported $1.32 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.74 by $0.58. Astrazeneca PLC had a return on equity of 31.30% and a net margin of 10.35%. The business earned $5.70 billion during the quarter, compared to analyst estimates of $5.95 billion. During the same quarter in the prior year, the business posted $1.03 EPS. Astrazeneca PLC’s revenue for the quarter was down 2.6% compared to the same quarter last year. Analysts forecast that Astrazeneca PLC will post $3.02 EPS for the current fiscal year.

Institutional investors have recently modified their holdings of the stock. Dodge & Cox raised its position in shares of Astrazeneca PLC by 24.9% in the second quarter. Dodge & Cox now owns 32,532,723 shares of the company’s stock valued at $982,163,000 after buying an additional 6,483,073 shares during the last quarter. Capital International Investors raised its position in shares of Astrazeneca PLC by 0.6% in the third quarter. Capital International Investors now owns 20,600,179 shares of the company’s stock valued at $676,922,000 after buying an additional 126,700 shares during the last quarter. Primecap Management Co. CA raised its position in shares of Astrazeneca PLC by 17.4% in the second quarter. Primecap Management Co. CA now owns 15,365,950 shares of the company’s stock valued at $463,898,000 after buying an additional 2,281,675 shares during the last quarter. BlackRock Investment Management LLC raised its position in shares of Astrazeneca PLC by 12.1% in the third quarter. BlackRock Investment Management LLC now owns 8,079,111 shares of the company’s stock valued at $265,480,000 after buying an additional 872,075 shares during the last quarter. Finally, Epoch Investment Partners Inc. raised its position in shares of Astrazeneca PLC by 1.8% in the third quarter. Epoch Investment Partners Inc. now owns 7,935,629 shares of the company’s stock valued at $260,765,000 after buying an additional 137,571 shares during the last quarter. 11.58% of the stock is currently owned by institutional investors.

About Astrazeneca PLC

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.

5 Day Chart for NYSE:AZN

Receive News & Stock Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related stocks with our FREE daily email newsletter.